Who Holds the IOU Holds the Vote
Foreign governments and central banks held about $4.69 trillion in U.S. Treasury bonds as of January 2026, according to the...
Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.
Foreign governments and central banks held about $4.69 trillion in U.S. Treasury bonds as of January 2026, according to the...
The story, briefly BioMarin's filed numbers show a business that has grown revenue by more than half over the past...
The standing BullScope yardsticks for ExxonMobil Holdings, computed from official filings and refreshed with each new edition.
The heart of it ExxonMobil's filed numbers show a company generating more free cash in a single quarter than most...
The standing BullScope yardsticks for Home Depot, computed from official filings and refreshed with each new edition.
The quick read Elanco's filed numbers show a business that spent five years losing money and is now generating real...
For the past year and a half, the Federal Reserve has been trying to cool prices without tipping the economy...
The standing BullScope yardsticks for Vertex Pharmaceuticals Inc / Ma, computed from official filings and refreshed with each new edition.
First, the shape of it The math, meaning what the filed numbers actually show, is a business earning 86 cents...
Here is the tension in one breath: Home Depot's stock has fallen roughly a fifth over the past year, yet...
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer